Edition:
United States

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

8.92USD
4:00pm EDT
Change (% chg)

$0.01 (+0.11%)
Prev Close
$8.91
Open
$8.92
Day's High
$9.20
Day's Low
$8.50
Volume
46,771
Avg. Vol
21,075
52-wk High
$9.21
52-wk Low
$2.13

Select another date:

Thu, May 17 2018

BRIEF-Biolife Solutions Announces Partial Redemption Of Series A Preferred Stock

* BIOLIFE SOLUTIONS ANNOUNCES PARTIAL REDEMPTION OF SERIES A PREFERRED STOCK Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions Reports Q1 Loss Per Share $0.01

* BIOLIFE SOLUTIONS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Casdin Capital To Become Shareholder In Biolife Solutions

* CASDIN CAPITAL LLC, ENTERED INTO AN AGREEMENT TO PURCHASE 1,000,000 BIOLIFE SOLUTIONS SHARES IN PRIVATE DEAL Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions Announces Preliminary Q1 Revenue Of $3.8 Mln, Up 61 Pct

* FOR 2018 BIOPRESERVATION MEDIA REVENUE EXPECTED TO RANGE BETWEEN $14.5 MILLION TO $15.5 MILLION

BRIEF-BioLife Solutions Q4 Loss Per Share $0.05

* BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Biolife Solutions Executes OEM Agreement With MilliporeSigma

* BIOLIFE SOLUTIONS EXECUTES OEM AGREEMENT WITH MILLIPORESIGMA Source text for Eikon: Further company coverage:

BRIEF-Biolife Solutions Says Co And Savsu Technologies Amended Their Arrangement With Respect To JV

* BIOLIFE SOLUTIONS SAYS ON JAN 22 CO AND SAVSU TECHNOLOGIES AMENDED THEIR ARRANGEMENT WITH RESPECT TO THEIR JV, BIOLOGISTEX- SEC FILING

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

Select another date: